Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Labetalol and its saltsF1 I SEP / 98
Lacosamide or its derivativesPDL I DEC / 13
Lactic acidPDL

when recommended for parenteral use as a tissue sclerosing agent

I DEC / 13
Lactic acid.

in preparations in concentrations of more than 10% except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses

III DEC / 14
Lactulose III SEP / 98
Lamivudine and its saltsF1 I SEP / 98
Lamotrigine and its saltsF1 I SEP / 98
Lanreotide and its saltsF1 I MAY / 09
Lansoprazole and its saltsF1 I SEP / 98
Lanthanum salts.F1 when sold for the treatment of hyperphosphatemia I FEB / 08
Lapatinib and its saltsF1 I MAR / 11
LaronidaseF1 I APR / 07
Ledipasvir or its saltsPDL I DEC / 14
Lefetamine and any Salt thereofC4 I JAN / 03
Leflunomide and its saltsF1 I DEC / 01
LenalidomideF1 I MAY / 09
Lenvatinib or its saltsPDL I AUG / 16
Letermovir or its saltsPDL I DEC / 17
LetrozoleF1 I SEP / 98
Leucovorin and its saltsF1 I SEP / 98
Leuprolide and its saltsF1 I SEP / 98
Levallorphane and its salts I SEP / 98
Levamisole and its saltsF2 I SEP / 98
Levargorphane and its salts II SEP / 98
LevetiracetamF1 I JUN / 06
Levobunolol and its saltsF1 I SEP / 98
Levocabastine and its salts and derivativesF1 I SEP / 98
Levocarnitine and its salts and derivativesF1 when sold for the treatment of primary or secondary levocarnitine deficiency I DEC / 11
Levodopa and its saltsF1 I SEP / 98
LevomethorphanN I JUN / 02
Levomilnacipran or its saltsPDL I JUN / 15
LevomoramideN I JUN / 02
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
LevophenacylmorphanN I JUN / 02
LevorphanolN I JUN / 02
LidocainePDL

when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher

I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its saltsPDL I MAR / 18
Linagliptin or its salts or derivativesPDL I DEC / 13
Lincomycin and its salts and derivativesF2 I SEP / 98
Lindane II SEP / 98
Linezolid and its saltsF1 I JUL / 03
Linezolid and its salts.F1 I JUN / 03
Liothyronine and its saltsF2 I SEP / 98
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its saltsPDL I DEC / 13
Lisinopril and its salts and derivativesF1 I SEP / 98
Lithium and its saltsF1 I SEP / 98
Lixisenatide or its saltsPDL I JUN / 17
Lodoxamide and its salts and derivativesF1 I SEP / 98
Lomefloxacin and its saltsF1 I SEP / 98
Lomitapide or its saltsPDL I FEB / 14
LomustineF1 I SEP / 98
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
LopinavirF1 I JUL / 03
LoprazolamTS I JUN / 02
Loracarbef and its salts and derivativesF1 I SEP / 98
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorazepam and its saltsTS I SEP / 98
LormetazepamTS I JUN / 02
Losartan and its saltsF1 I SEP / 98
Losoxantrone and its saltsF1 I SEP / 98
LotilanerPDL

For veterinary use

I MAR / 18
LovastatinPDL

except in oral dosage form that provides 1 milligram (mg) or less per daily dose

I DEC / 14
Loxapine and its saltsF1 I SEP / 98
Lumacaftor or its salts or derivativesPDL I AUG / 16
LumiracoxibF1 I MAY / 09
Lutropin alfaF1 I OCT / 07
Lyme Disease vaccine I FEB / 02

76 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled